Home > Healthcare & Medical Devices > Sleep Disorder Market

Sleep Disorder Market Size By Disorder Type (Sleep Apnea {Obstructive Sleep Apnea, Central Sleep Apnea, Complex Sleep Apnea}, Insomnia, Restless Legs Syndrome (RLS), Narcolepsy), By Product (Diagnostics {Actigraphy Systems Polysomnography {PSG} Device, Respiratory Polygraph, Sleep Screening Devices, Home Sleep Tests}, Therapeutics {Cognitive Behavioral Therapy, Therapeutic Devices [Airway Clearance System, Adaptive Servo-ventilation (ASV), Positive Airway Pressure (PAP) Devices, Oral Appliances, Oxygen Devices], Medication Therapy [Benzodiazepines, Dual Orexin Receptor Antagonists, Melatonin Receptor Agonists, Antidepressants, Others]}), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

  • Report ID: GMI5172
  • Published Date: Dec 2021
  • Report Format: PDF

Industry trends

Sleep Disorder Market size exceeded USD 13.3 billion in 2020 and is estimated to witness 6.6% CAGR from 2021 to 2027. Surging prevalence of sleep disorders such as sleep apnea, narcolepsy and insomnia across the globe is likely to drive the industry growth.
 

Sleep Disorder Market Overview

Get more details on this report - Request Free Sample PDF
 

The availability of effective diagnosis and treatment of the disorder is further likely to fuel the market progression. Moreover, COVID-19 impact on the industry is observed to be significant during the COVID-19 pandemic as the instances of sleep disorders saw a surge. For instance, a study from Lancet stated that, sleep problems became common during the COVID-19 pandemic due to higher levels of psychological distress. However, despite the cases being high, the market was hampered by lockdowns, disruption in supply chain, and postponing of non-emergency cases. The industry is expected to bolster in the coming years as situations are heading to new normal.
 

Product innovation by companies and technological advancements in devices

Technological advancements such as development of advanced sleep diagnostic and therapeutic devices will escalate the sleep disorder market growth. For instance, in February 2021, The US Food and Drug Administration has authorised the sale of eXciteOSA, a novel prescription-only device designed to reduce snoring and moderate obstructive sleep apnea. The device works by administering electrical muscle stimulation through a mouthpiece that rests around the tongue, which allows for optimal ventilation. Additionally, it is s the first marketed device designed to be used while awake.
 

Surging cases of sleep apnea

Sleep Disorder Market Size

Get more details on this report - Request Free Sample PDF
 

The sleep apnea segment is poised to register 6.8% gains through 2027. In person suffering with sleep apnea, the breathing stops repeatedly for 10 seconds or more during the sleep. A report from American sleep Apnea Association stated that, around 22 million Americans are currently suffering from sleep apnea. This has created demand for sleep apnea devices such as PAP devices, masks, and sleep ventilators. Furthermore, the increasing trend of oral appliances and home sleep care for the management of sleep apnea will spur the market revenue.
 

Surging demand for sleep diagnostic devices will favor the sleep disorder market space

The diagnostics segment accounted for more than USD 814.2 million revenue in 2020 owing to growing demand for sleep disorder diagnosis. Additionally, development of new diagnostic devices is propelling the industry statistics. For instance, in December 2020, a Belgian startup ‘Sunrise’, in collaboration with institutions such as National Heart and Lung Institute and Imperial college the company launched a chin sensor to diagnose sleep apnea. It is world’s first sleep test device that detects sleep disorders using a device that sits on patient’s chin.
 

Increasing awareness programs regarding sleep disorders in North America

North America Sleep Disorder Market

Get more details on this report - Request Free Sample PDF
 

North America sleep disorder market captured above 44% of the revenue share in 2020 and is projected to grow substantially through 2027 driven by the increasing funding on awareness program about sleep disorder. Moreover, increasing expenditure on healthcare, presence of well-established healthcare sector will augment the industry development. The increasing number of new products launches as well as the high penetration of key players in the region is boosting the market demand.
 

Presence of numerous companies will enhance the industry expansion

Some of the prominent sleep disorder market players include, Astellas Pharma Inc, Cadwell Laboratories Inc., Cardinal Health, Compumedics Limited, Eisai Co Ltd, Evotec AG, Ferring International Center SA, GlaxoSmithKline plc, Heptares Therapeutics Ltd, Koninklijke Philips N.V., Natus Medical Incorporated, ResMed Inc., Somnetics International, Inc., Takeda Pharmaceutical Company Limited, Teleflex Inc., and Teva Pharmaceutical Industries Ltd., among others. Companies are implementing various growth strategies to sustain market competition.
 

This market research report on sleep disorder includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Disorder Type, 2016-2027 (USD Million)

  • Sleep apnea
    • Obstructive sleep apnea
    • Central sleep apnea
    • Complex sleep apnea
  • Insomnia
  • Restless legs syndrome (RLS)
  • Narcolepsy
  • Others

Market, By Product, 2016-2027 (USD Million)

  •  Diagnostics
    • Actigraphy systems
    • Polysomnography (PSG) device
    • Respiratory polygraph
    • Sleep screening devices
    • Home sleep tests
    • Others
  • Therapeutics
    • Cognitive behavioral therapy
    • Therapeutic devices
      • Airway clearance system
      • Adaptive servo-ventilation (ASV)
      • Positive airway pressure (PAP) devices
      • Oral appliances
      • Oxygen devices
      • Others
    • Medication therapy
      • Benzodiazepines
      • Dual orexin receptor antagonists
      • Melatonin receptor agonists
      • Antidepressants
      • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • South Africa

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The market size of sleep disorder crossed USD 13.3 billion in 2020 and will record a CAGR of over 6.6% through 2027, says this GMI report.

Diagnostics segment had accounted for a valuation of around USD 814.2 million in 2020 owing to the elevating product demand along with the ongoing product innovations.

Sleep apnea segment will exhibit a CAGR of about 6.8% through 2027 with the increasing pervasiveness of obesity, high blood pressure, diabetes, and congestive heart failure.

North America captured more than 44% of the market share in 2020 on account of the increasing funding initiatives to create awareness about sleeping disorders such as sleep apnea.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Base Year: 2020
  • Companies covered: 16
  • Tables & Figures: 220
  • Countries covered: 19
  • Pages: 246

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount